{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:05:18Z","timestamp":1781625918267,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) has improved survival outcomes with advancements in immunosuppressive therapies; however, the increased incidence of infections remains a significant concern. Reports on infection risk factors other than age are limited, especially in older adults with AAV who are at a higher risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We aimed to identify the risk factors for early-phase infection during treatment initiation in older adults (aged\u2009\u2265\u200975 years) with myeloperoxidase (MPO)-ANCA-positive AAV (MPO-AAV). This was a single-center, retrospective observational study that included 50 patients who were classified as having microscopic polyangiitis. Severe infections were defined as those requiring hospitalization within six months of treatment initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Severe infections occurred in 17 (34%) patients. No statistically significant associations were observed between disease incidence and either combined immunosuppressive therapy or organ-specific lesions. However, trimethoprim-sulfamethoxazole (TMP-SMX) was significantly associated with a reduced risk of infection. This association remained statistically significant after adjustment for sex (hazard ratio, 0.23; 95% CI, 0.08\u20130.64;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In older adults with MPO-AAV, TMP-SMX use was associated with a reduced risk of early severe infection. Although limited by the observational nature of the study, these findings suggest a potential role for TMP-SMX prophylaxis in high-risk elderly populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-025-04695-y","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T16:46:24Z","timestamp":1765989984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Trimethoprim-sulfamethoxazole and the risk of early severe infection in elderly-onset myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis"],"prefix":"10.1186","volume":"27","author":[{"given":"Shun","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Osano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Shikata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihisa","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Nakagomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Uchimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumu","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"4695_CR1","doi-asserted-by":"crossref","unstructured":"Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65:1\u201311.","DOI":"10.1002\/art.37715"},{"key":"4695_CR2","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3899\/jrheum.130602","volume":"41","author":"S Furuta","year":"2014","unstructured":"Furuta S, Chaudhry AN, Hamano Y, Fujimoto S, Nagafuchi H, Makino H, et al. Comparison of phenotype and outcome in microscopic polyangiitis between Europe and Japan. J Rheumatol. 2014;41:325\u201333.","journal-title":"J Rheumatol"},{"key":"4695_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41584-021-00718-8","volume":"18","author":"RA Watts","year":"2022","unstructured":"Watts RA, Hatemi G, Burns JC, Mohammad AJ. Global epidemiology of vasculitis. Nat Rev Rheumatol. 2022;18:22\u201334.","journal-title":"Nat Rev Rheumatol"},{"key":"4695_CR4","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3899\/jrheum.160005","volume":"44","author":"S Furuta","year":"2017","unstructured":"Furuta S, Chaudhry AN, Arimura Y, Dobashi H, Fujimoto S, Homma S, et al. Comparison of the phenotype and outcome of granulomatosis with polyangiitis between UK and Japanese cohorts. J Rheumatol. 2017;44:216\u201322.","journal-title":"J Rheumatol"},{"key":"4695_CR5","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1093\/rheumatology\/ker205","volume":"50","author":"S Fujimoto","year":"2011","unstructured":"Fujimoto S, Watts RA, Kobayashi S, Suzuki K, Jayne DR, Scott DG, et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. Rheumatology (Oxford). 2011;50:1916\u201320.","journal-title":"Rheumatology (Oxford)"},{"key":"4695_CR6","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1002\/art.40313","volume":"69","author":"A Berti","year":"2017","unstructured":"Berti A, Cornec D, Crowson CS, Specks U, Matteson EL. The epidemiology of antineutrophil cytoplasmic Autoantibody-Associated vasculitis in olmsted County, minnesota: A Twenty-Year US Population-Based study. Arthritis Rheumatol. 2017;69:2338\u201350.","journal-title":"Arthritis Rheumatol"},{"key":"4695_CR7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","volume":"83","author":"B Hellmich","year":"2024","unstructured":"Hellmich B, Sanchez-Alamo B, Schirmer JH, Berti A, Blockmans D, Cid MC, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024;83:30\u201347.","journal-title":"Ann Rheum Dis"},{"key":"4695_CR8","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/art.41773","volume":"73","author":"SA Chung","year":"2021","unstructured":"Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, et al. 2021 American college of Rheumatology\/Vasculitis foundation guideline for the management of antineutrophil cytoplasmic Antibody-Associated vasculitis. Arthritis Rheumatol. 2021;73:1366\u201383.","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 1","key":"4695_CR9","doi-asserted-by":"publisher","first-page":"i171","DOI":"10.1093\/ndt\/gfv045","volume":"30","author":"JG McGregor","year":"2015","unstructured":"McGregor JG, Negrete-Lopez R, Poulton CJ, Kidd JM, Katsanos SL, Goetz L, et al. Adverse events and infectious burden, microbes and Temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function. Nephrol Dial Transpl. 2015;30(Suppl 1):i171\u2013181.","journal-title":"Nephrol Dial Transpl"},{"key":"4695_CR10","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/eci.12410","volume":"45","author":"A Kronbichler","year":"2015","unstructured":"Kronbichler A, Jayne DR, Mayer G. Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Invest. 2015;45:346\u201368.","journal-title":"Eur J Clin Invest"},{"key":"4695_CR11","doi-asserted-by":"publisher","first-page":"e2220925","DOI":"10.1001\/jamanetworkopen.2022.20925","volume":"5","author":"S Thietart","year":"2022","unstructured":"Thietart S, Karras A, Augusto JF, Philipponnet C, Carron PL, Delbrel X, et al. Evaluation of rituximab for induction and maintenance therapy in patients 75 years and older with antineutrophil cytoplasmic Antibody-Associated vasculitis. JAMA Netw Open. 2022;5:e2220925.","journal-title":"JAMA Netw Open"},{"key":"4695_CR12","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1136\/ard.2010.137778","volume":"70","author":"O Flossmann","year":"2011","unstructured":"Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011;70:488\u201394.","journal-title":"Ann Rheum Dis"},{"key":"4695_CR13","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1093\/rheumatology\/keaa699","volume":"60","author":"J Rathmann","year":"2021","unstructured":"Rathmann J, Jayne D, Segelmark M, J\u00f6nsson G, Mohammad AJ. Incidence and predictors of severe infections in ANCA-associated vasculitis: a population-based cohort study. Rheumatology (Oxford). 2021;60:2745\u201354.","journal-title":"Rheumatology (Oxford)"},{"key":"4695_CR14","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/j.semarthrit.2020.02.008","volume":"50","author":"A Berti","year":"2020","unstructured":"Berti A, Felicetti M, Monti S, Ortolan A, Padoan R, Brunori G, et al. Disease and treatment-related morbidity in young and elderly patients with granulomatosis with polyangiitis and microscopic polyangiitis. Semin Arthritis Rheum. 2020;50:1441\u20138.","journal-title":"Semin Arthritis Rheum"},{"key":"4695_CR15","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.2215\/CJN.00480115","volume":"10","author":"M Weiner","year":"2015","unstructured":"Weiner M, Goh SM, Mohammad AJ, Hruskova Z, Tanna A, Bruchfeld A, et al. Outcome and treatment of elderly patients with ANCA-associated vasculitis. Clin J Am Soc Nephrol. 2015;10:1128\u201335.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4695_CR16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s12882-018-1102-3","volume":"19","author":"D Titeca-Beauport","year":"2018","unstructured":"Titeca-Beauport D, Francois A, Lobbedez T, Guerrot D, Launay D, Vrigneaud L, et al. Early predictors of one-year mortality in patients over 65 presenting with ANCA-associated renal vasculitis: a retrospective, multicentre study. BMC Nephrol. 2018;19:317.","journal-title":"BMC Nephrol"},{"key":"4695_CR17","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12882-018-0933-2","volume":"19","author":"L Yang","year":"2018","unstructured":"Yang L, Xie H, Liu Z, Chen Y, Wang J, Zhang H, et al. Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study. BMC Nephrol. 2018;19:138.","journal-title":"BMC Nephrol"},{"key":"4695_CR18","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1093\/mr\/roac150","volume":"33","author":"K Nagasaka","year":"2023","unstructured":"Nagasaka K, Amano K, Dobashi H, Nagafuchi H, Sada KE, Komagata Y, et al. Nation-wide cohort study of remission induction therapy using rituximab in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: effectiveness and safety in the first 6 months. Mod Rheumatol. 2023;33:1117\u201324.","journal-title":"Mod Rheumatol"},{"key":"4695_CR19","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3899\/jrheum.190065","volume":"47","author":"E Garcia-Vives","year":"2020","unstructured":"Garcia-Vives E, Segarra-Medrano A, Martinez-Valle F, Agraz I, Solans-Laque R. Prevalence and risk factors for major infections in patients with antineutrophil cytoplasmic Antibody-associated vasculitis: influence on the disease outcome. J Rheumatol. 2020;47:407\u201314.","journal-title":"J Rheumatol"},{"key":"4695_CR20","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1080\/14397595.2016.1226468","volume":"27","author":"K Watanabe-Imai","year":"2017","unstructured":"Watanabe-Imai K, Harigai M, Sada KE, Yamamura M, Fujii T, Dobashi H, et al. Clinical characteristics of and risk factors for serious infection in Japanese patients within six months of remission induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis registered in a nationwide, prospective, inception cohort study. Mod Rheumatol. 2017;27:646\u201351.","journal-title":"Mod Rheumatol"},{"key":"4695_CR21","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1136\/annrheumdis-2017-212861","volume":"77","author":"A Kronbichler","year":"2018","unstructured":"Kronbichler A, Kerschbaum J, Gopaluni S, Tieu J, Alberici F, Jones RB, et al. Trimethoprim-sulfamethoxazole prophylaxis prevents severe\/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2018;77:1440\u20137.","journal-title":"Ann Rheum Dis"},{"key":"4695_CR22","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1007\/s00296-021-04891-7","volume":"41","author":"K Yamaguchi","year":"2021","unstructured":"Yamaguchi K, Yamaguchi A, Itai M, Onuki Y, Shin Y, Uno S, et al. Interstitial lung disease with myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis in elderly patients. Rheumatol Int. 2021;41:1641\u201350.","journal-title":"Rheumatol Int"},{"key":"4695_CR23","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s13075-020-02341-6","volume":"22","author":"KE Sada","year":"2020","unstructured":"Sada KE, Ohashi K, Asano Y, Hayashi K, Morishita M, Watanabe H, et al. Treatment-related damage in elderly-onset ANCA-associated vasculitis: safety outcome analysis of two nationwide prospective cohort studies. Arthritis Res Ther. 2020;22:236.","journal-title":"Arthritis Res Ther"},{"key":"4695_CR24","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1007\/s10067-018-4067-5","volume":"37","author":"J Yoo","year":"2018","unstructured":"Yoo J, Jung SM, Song JJ, Park YB, Lee SW. Birmingham vasculitis activity and chest manifestation at diagnosis can predict hospitalised infection in ANCA-associated vasculitis. Clin Rheumatol. 2018;37:2133\u201341.","journal-title":"Clin Rheumatol"},{"key":"4695_CR25","doi-asserted-by":"publisher","first-page":"1110548","DOI":"10.3389\/fmed.2023.1110548","volume":"10","author":"A Vassilopoulos","year":"2023","unstructured":"Vassilopoulos A, Vassilopoulos S, Kalligeros M, Shehadeh F, Mylonakis E. Incidence of serious infections in patients with ANCA-associated vasculitis receiving immunosuppressive therapy: A systematic review and meta-analysis. Front Med (Lausanne). 2023;10:1110548.","journal-title":"Front Med (Lausanne)"},{"key":"4695_CR26","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1136\/annrheumdis-2021-221794","volume":"81","author":"PC Grayson","year":"2022","unstructured":"Grayson PC, Ponte C, Suppiah R, Robson JC, Craven A, Judge A, et al. 2022 American college of rheumatology\/European alliance of associations for rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis. 2022;81:309\u201314.","journal-title":"Ann Rheum Dis"},{"key":"4695_CR27","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1136\/annrheumdis-2021-221795","volume":"81","author":"JC Robson","year":"2022","unstructured":"Robson JC, Grayson PC, Ponte C, Suppiah R, Craven A, Judge A, et al. 2022 American college of rheumatology\/European alliance of associations for rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis. 2022;81:315\u201320.","journal-title":"Ann Rheum Dis"},{"key":"4695_CR28","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/art.41983","volume":"74","author":"R Suppiah","year":"2022","unstructured":"Suppiah R, Robson JC, Grayson PC, Ponte C, Craven A, Khalid S, et al. 2022 American college of rheumatology\/European alliance of associations for rheumatology classification criteria for microscopic polyangiitis. Arthritis Rheumatol. 2022;74:400\u20136.","journal-title":"Arthritis Rheumatol"},{"key":"4695_CR29","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"4695_CR30","first-page":"61","volume":"14","author":"FI Mahoney","year":"1965","unstructured":"Mahoney FI, Barthel DW. FUNCTIONAL EVALUATION: THE BARTHEL INDEX. Md State Med J. 1965;14:61\u20135.","journal-title":"Md State Med J"},{"key":"4695_CR31","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1136\/ard-2022-223401","volume":"82","author":"B Odler","year":"2023","unstructured":"Odler B, Riedl R, Gauckler P, Shin JI, Leierer J, Merkel PA, et al. Risk factors for serious infections in ANCA-associated vasculitis. Ann Rheum Dis. 2023;82:681\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 129","key":"4695_CR32","doi-asserted-by":"publisher","first-page":"142","DOI":"10.55563\/clinexprheumatol\/p34lkr","volume":"39","author":"D Waki","year":"2021","unstructured":"Waki D, Nishimura K, Yoshida T, Tanaka N, Mizukawa K, Fukushima M, et al. Protective effect of different doses of trimethoprim-sulfamethoxazole prophylaxis for early severe infections among patients with antineutrophil cytoplasmic autoantibody-associated vasculitis. Clin Exp Rheumatol. 2021;39(Suppl 129):142\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"4695_CR33","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363:211\u201320.","journal-title":"N Engl J Med"},{"key":"4695_CR34","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221\u201332.","journal-title":"N Engl J Med"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04695-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04695-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04695-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:20:02Z","timestamp":1781623202000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-025-04695-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4695"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04695-y","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"23 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the tenets of the Declaration of Helsinki and was approved by the Ethical Review Committee of Yamanashi University (approval number: 2855, registered on September 30, 2024). The Ethics Review Committee of Yamanashi University waived the requirement for written informed consent for retrospective observational studies in accordance with local regulations. All data were fully anonymized before the analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}